Treatment News : ICAAC: MK-0518 Potent for Treatment Experienced - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2006

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 29, 2006

ICAAC: MK-0518 Potent for Treatment Experienced

by Tim Horn

September 29, 2006 (AIDSmeds)—New follow-up data from a clinical trial evaluating Merck's experimental integrase inhibitor MK-0518 in HIV-positive people who have tried and failed other HIV medications in the past indicates that the drug is effective in terms of reducing viral load for at least 24 weeks. The study, evaluating an optimized background regimen (OBR) combined with either MK-0518 or placebo, also suggests that drug combinations containing MK-0518 are relatively well tolerated.

The results were reported Friday during a late-breaker presentation at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco. Twenty-four weeks of follow-up data were reported by Beatriz Grinsztein, MD, PhD, of the Evandro Chagas Clinical Research Institute in Rio De Janeiro, Brazil. Sixteen-week data from the trial were reported at the 13th Conference on Retroviruses and Opportunistic Infection (CROI) in Denver in February and arrive on the heels of encouraging results from a another study, reported at the XVI International AIDS Conference in Toronto, evaluating MK-0518 in HIV-positive people starting therapy for the first time.

The clinical trial compared MK-0518/OBR to placebo/OBR with respect to changes in viral load and CD4 (T4) cell counts, along with safety and tolerability. Enrolled study volunteers received one of three doses of MK-0518 (200mg, 400mg, or 600mg) or placebo – both taken twice daily – plus OBR consisting of available HIV drugs that were selected using drug resistance testing.

Twenty-four week follow-up data were available for 178 patients enrolled in the study. On average, these patients had been on some form of HIV therapy for nine years and had viral loads between 40,000 and 70,000 upon entering the trial. Their CD4 cell counts, prior to beginning either MK-0518 or placebo, ranged from 220 to 274.

After almost six months of treatment, 57% to 67% of those taking MK-0518 plus OBR had viral loads below 50. Among those taking placebo plus OBR, only 14% had viral loads below this level. The viral load reductions seen were statistically significant, meaning that the differences between the two groups weren't likely due to chance.

A number of patients enrolled in the study used OBR that, according to the results of drug resistance testing, was not active against their highly drug-resistant virus. In other words, these patients were essentially using only one active agent: MK-0518. After 24 weeks, between 46% and 62% of these patients had viral loads below 50. None of the patients combining placebo with ineffective OBR had viral loads below 50.

MK-0518, at all doses studied, plus OBR was reported to be generally well tolerated and comparable to placebo plus OBR. The most common side effects were diarrhea, nausea, fatigue, headache, and itching. Four patients discontinued treatment due these (or other) adverse effects.

Source:

Grinsztejn B, Nguyen B, Katlama C, et al. Efficacy of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus: 24-week data [Abstract H-1670b]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006.


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    Loveladyd
    Washington
    DC


    latinpozdallas
    Dallas
    Texas


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.